NEW YORK – Codetta Biosciences said on Thursday that it has raised $15 million in Series A financing. The round was led by Anzu Partners, with additional support from Genoa Ventures and VC23.
The Morrisville, North Carolina-based life sciences company said it will use the funds to accelerate the development of its multiomic digital spatial polymerase chain reaction (dsPCR) platform and "aggressively scale up" its workforce in R&D, engineering, marketing, and business administration.
Codetta said it aims to develop an integrated platform of reagents, hardware, and software for multiplexed, quantitative, and simultaneous multiomic analyses of DNA, RNA, and proteins in isolation or in liquid biopsy samples. The company claimed its technology will allow researchers to analyze viral and bacterial targets, mutations, and deletions, as well as gene and protein expression more efficiently than conventional technologies.
"With simultaneous detection of DNA, RNA, and protein analytes and ultra-sensitivity, Codetta enables broad molecular profiling, empowering minimum residual disease (MRD), biomarker, and infectious disease assessment," said John Ho, a partner at Anzu Partners, in a statement.